⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8698241 | 0.67 | — | — | |
| SCHEMBL11147635 | 0.67 | — | — | |
| SCHEMBL440940 | 0.64 | — | — | |
| SCHEMBL454419 | 0.64 | — | — | |
| SCHEMBL4737874 | 0.64 | — | — | |
| SCHEMBL19348645 | 0.64 | — | — | |
| SCHEMBL440939 | 0.64 | — | — | |
| SCHEMBL6688533 | 0.62 | — | — | |
| SCHEMBL50123 | 0.61 | — | — | |
| SCHEMBL17004026 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138964-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | TRANSCEND THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250270242-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | TRANSCEND THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4605385-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | Transcend Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4573084-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | Transcend Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12297220-B2 | Phenethylamines and cathinones precursors | TRANSCEND THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250129108-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | TRANSCEND THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240374558-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | TRANSCEND THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| WO-2024039599-A9 | PHENETHYLAMINES AND CATHINONES PRECURSORS | TRANSCEND THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240327372-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | TRANSCEND THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024086218-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | TRANSCEND THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-101648977-B | 2,2',6,6'site connected 1,1'-diphenyl axially chiral bi-phosphoramide and phosphorous acid ester ligand and preparation method thereof | UNIV SHANGHAI JIAOTONG | 2013-04-24 | — | — | CN | disclosed |
| CN-102395590-A | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | RFS PHARMA LLC | 2012-03-28 | — | — | CN | disclosed |
| EP-2351844-A1 | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells | AVI BioPharma, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-1629105-B1 | COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS | AVI BIOPHARMA INC (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101648977-A | 2,2',6,6'site connected 1,1'-diphenyl axially chiral bi-phosphoramide and phosphorous acid ester ligand and preparation method thereof | UNIV SHANGHAI JIAOTONG | 2010-02-17 | — | — | CN | disclosed |
| US-20090082547-A1 | COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO CELLS | SAREPTA THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7468418-B2 | peptide nucleic acid conjugate of a nucleic acid analog covalently linked to a peptide transporter moiety; enhance antisense activity; drug delivery; conjugate is a morpholino-base with phosphorodiamidate linkages with a peptide such as Arg9Phe2 (arginine9phenylalanine2) | AVI BIOPHARMA., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1629105-A2 | COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS | Avi Biopharma, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20040265879-A1 | peptide nucleic acid conjugate of a nucleic acid analog covalently linked to a peptide transporter moiety; enhance antisense activity; drug delivery; conjugate is a morpholino-base with phosphorodiamidate linkages with a peptide such as Arg9Phe2 (arginine9phenylalanine2) | SAREPTA THERAPEUTICS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004097017-A2 | COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS | AVI BIOPHARMA, INC. (US) | 2004-11-11 | — | — | WO | disclosed |